首页> 外文期刊>Journal of Medicinal Chemistry >Novel Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Anti-Inflammatory and Analgesic Agents. Synthesis and in Vitro and in Vivo Biological Evaluation
【24h】

Novel Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Anti-Inflammatory and Analgesic Agents. Synthesis and in Vitro and in Vivo Biological Evaluation

机译:1,5-二芳基吡咯支架的新型酯和酸衍生物作为抗炎和镇痛药。合成,体外和体内生物学评估

获取原文
获取原文并翻译 | 示例
       

摘要

A new generation of selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) was developed to circumvent the major side effects of cyclooxygenase-1 (COX-1) and COX-2 inhibitors (stomach ulceration and nephrotoxicity). As a consequence, coxibs are extremely valuable in treating acute and chronic inflammatory conditions. However, the use of coxibs, such as rofecoxib (Vioxx), was discontinued because of the high risk of cardiovascular adverse events. More recent clinical findings highlighted how the cardiovascular toxicity of coxibs could be mitigated by an appropriate COX-1 versus COX-2 selectivity. We previously reported a set of substituted 1,5-diarylpyrrole derivatives, selective for COX-2. Here, we describe the synthesis of new1,5-diarylpyrroles along with their inhibitory effects in vitro, ex vivo, and in vivo toward COX isoenzymes and their analgesic activity. Isopropyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrrole-3-acetate (10a), a representative member of the series, was selected for pharmacokinetic and metabolic studies.
机译:开发了新一代的选择性环氧合酶2(COX-2)抑制剂(coxibs),以规避环氧合酶1(COX-1)和COX-2抑制剂的主要副作用(胃溃疡和肾毒性)。结果,coxibs在治疗急性和慢性炎性疾病方面非常有价值。然而,由于心血管不良事件的高风险,已停止使用罗非昔布(Vioxx)等考昔布。最近的临床发现强调了通过适当的COX-1与COX-2选择性可以如何缓解Coxib的心血管毒性。我们先前报道了一组对COX-2具有选择性的取代1,5-二芳基吡咯衍生物。在这里,我们描述了新的1,5-二芳基吡咯的合成及其在体外,离体和体内对COX同工酶及其止痛活性的抑制作用。选择该系列的代表成员异丙基-2-甲基-5- [4-(甲基磺酰基)苯基] -1-苯基-1H-吡咯-3-乙酸酯(10a)进行药代动力学和代谢研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号